Ovarian Cancer Metastasis to the Stomach: Symptoms & Treatment

Ovarian cancer spreading to the stomach is an exceptionally rare event, even among advanced-stage cases where the disease has already moved beyond the pelvis. A literature review analyzing gynecologic cancers that metastasized to the stomach found data on only 18 patients with ovarian-origin gastric metastases, compared with 159 cases originating from breast cancer.¹ Because this presentation is so uncommon, it often catches both patients and clinicians off guard, and the symptoms it produces can be frustratingly similar to those of advanced ovarian cancer itself.

How Ovarian Cancer Reaches the Stomach

Ovarian cancer is well known for spreading across the peritoneal surfaces, the membranes lining the abdomen. Cancer cells shed from the ovary, float in peritoneal fluid, and implant on nearby organs. The stomach sits in the upper abdomen covered partially by the peritoneum, so it can become a landing site for these floating cells. But direct surface implantation is not the only route. Research using labeled cancer cells in an animal model showed that ovarian cancer cells injected into the peritoneal cavity traveled to remote organs by way of the lymphatic system, clearly demonstrating that lymphatic channels carry ovarian cancer well beyond the immediate abdominal lining.² Hematogenous spread through the bloodstream is also possible but appears even less common for gastric involvement.

The practical takeaway is that ovarian cancer reaching the stomach usually reflects advanced peritoneal disease, not a random jump. Most patients who develop gastric involvement have already been living with widespread peritoneal carcinomatosis for some time. One case series found that the median interval between the initial ovarian cancer diagnosis and the discovery of a gastric metastasis was about 30 months.³ That lag matters because it means gastric metastases tend to emerge during recurrence rather than at first diagnosis.

What Symptoms Look Like

The difficulty with gastric metastasis from ovarian cancer is that its symptoms overlap heavily with those of the underlying disease. Persistent abdominal distension, loss of appetite, and feeling full after eating very little are hallmark complaints in ovarian cancer generally. A study examining symptom patterns found that persistent abdominal distension, appetite loss, and early satiety were each independently and significantly associated with ovarian cancer, with persistent distension present in over 86% of women later diagnosed.⁴ When the stomach itself is involved, these same symptoms intensify or change character, but because they already exist in most patients with advanced disease, the new gastric component can hide in plain sight.

Symptoms that point more specifically toward stomach involvement include:

Nausea and vomiting: Especially new-onset or worsening vomiting in someone whose disease had been relatively stable, suggesting the tumor is physically obstructing the stomach or its outlet.
Upper abdominal pain: A shift from diffuse lower-abdominal discomfort to pain localized higher up, near the rib cage or epigastric area.
Gastrointestinal bleeding: Dark or tarry stools, or occasionally vomiting blood. One case report described a gastric metastasis from ovarian cancer that first revealed itself through digestive hemorrhage.⁵
Progressive difficulty eating: Meals that once were tolerable become impossible, with fullness setting in after a few bites or food seeming to “stick.”

Because abdominal discomfort is so central to ovarian cancer at every stage, validated symptom tools have been developed specifically for this population. A four-item subscale for abdominal discomfort was tested in women with advanced ovarian cancer undergoing treatment and reliably captured changes in abdominal symptoms over time.⁶ The point for patients is that new or worsening upper gastrointestinal symptoms during follow-up deserve attention and should not be dismissed as “just part of the cancer.” They can signal a treatable complication.

How Gastric Metastases Are Found

Most gastric metastases from ovarian cancer are discovered during endoscopy performed to investigate new symptoms. What the doctor sees through the scope, however, can be misleading. In one reported case, endoscopy revealed a small elevated lesion with ulceration on its surface in the stomach.² In another, the lesion looked entirely different: a smooth, round mass beneath the stomach lining, covered with normal-appearing mucosa, closely mimicking a benign stromal tumor. Endoscopic ultrasound in that case showed the mass invading into the muscle layer with a well-defined border, which further reinforced the resemblance to a benign growth.⁷

That variability is a real problem. In one case series of gastric metastases from ovarian cancer, about two-thirds of the lesions appeared as submucosal tumors on endoscopy.³ A submucosal tumor sits beneath the inner lining of the stomach, so a standard biopsy that only scrapes the surface may miss it entirely. Deeper biopsies or endoscopic ultrasound-guided sampling are often needed to reach the abnormal tissue and get a diagnosis. When a woman with a known history of ovarian cancer develops a new stomach mass, clinicians have to keep metastatic disease on the differential even if the endoscopic appearance suggests something else.

Telling It Apart From a Primary Stomach Cancer

This is where tissue analysis becomes essential. Under the microscope, a metastatic ovarian tumor in the stomach can look remarkably similar to a primary gastric cancer, particularly certain subtypes. The distinction matters enormously because treatment plans, expected response to chemotherapy, and prognosis all differ depending on where the cancer originated.

Immunohistochemistry, a method of staining tissue samples to identify specific proteins, is the main tool for sorting this out. Ovarian cancers tend to express high levels of a protein called CK7 and low levels of CK20, while gastric cancers show the opposite pattern or express both. A systematic meta-analysis confirmed that CK7 expression was significantly greater in ovarian carcinoma than in gastric carcinoma, while CK20 and carcinoembryonic antigen (CEA) were more characteristic of gastric origin.⁸ Additional markers like the gastric mucin gene MUC5AC can also help flag a gastric origin.⁹

Getting this right prevents the wrong chemotherapy regimen and avoids unnecessary surgery. A patient with ovarian cancer metastatic to the stomach needs platinum-based ovarian cancer treatment, not the regimen you would use for a new primary stomach cancer. Misidentification can cost time that a patient with advanced disease does not have.

The Krukenberg Tumor Confusion

A common point of confusion is the Krukenberg tumor, which is essentially the reverse scenario: a gastric (stomach) cancer that has metastasized to the ovary. Krukenberg tumors are far more common than ovarian-to-stomach spread, and they have been known to medicine much longer. The two situations can look similar on imaging and even under the microscope, especially when the patient has a mass involving both the stomach and the ovary and the primary site is unclear.

The immunohistochemistry patterns described above help resolve the ambiguity. A CK20-positive, CK7-negative pattern points toward a gastric primary that has spread to the ovary, while a CK7-positive, CK20-negative pattern supports an ovarian primary.⁹ Clinical history also plays a role: a patient who was first diagnosed with ovarian cancer years earlier and now has a stomach lesion is a very different situation from a patient presenting with simultaneous ovarian and gastric masses and no prior cancer diagnosis. In the latter case, gastric-to-ovary spread (Krukenberg) should be considered first, since it is statistically much more likely.

Treatment When Ovarian Cancer Has Spread to the Stomach

Treatment follows the general framework for advanced ovarian cancer but with added considerations for managing the stomach involvement specifically. The backbone of care has several components, and what combination a patient receives depends on the extent of disease, her overall health, and how the cancer has responded to prior treatments.

Systemic Chemotherapy

The cornerstone of advanced ovarian cancer treatment remains platinum-based chemotherapy, typically a combination of carboplatin and paclitaxel. In a study of patients with advanced ovarian cancer treated with this regimen as first-line therapy, about 81% responded to treatment, with mean overall survival reaching 20 months.¹⁰ When the stomach is involved, the same systemic therapy can shrink metastatic deposits there, because the drugs circulate throughout the body and reach all sites of disease. Systemic treatment is generally considered the preferred strategy for gastric metastases from ovarian cancer, rather than rushing to operate on the stomach itself.³

Cytoreductive Surgery

Aggressive surgery to remove as much visible tumor as possible remains a central part of ovarian cancer management. When disease has spread to the stomach, the surgical team evaluates whether a partial gastrectomy (removal of part of the stomach) can achieve complete or near-complete removal of all visible cancer. This decision is highly individualized. The surgery adds complexity and recovery time, and it is only justified when the team believes that removing the gastric involvement will meaningfully improve the patient’s outcome rather than simply adding surgical risk. In recurrent disease especially, the benefit of resecting gastric deposits has to be weighed carefully against the patient’s ability to tolerate the procedure.

HIPEC

Heated intraperitoneal chemotherapy, known as HIPEC, is a single intraoperative procedure in which chemotherapy is circulated directly inside the abdominal cavity at an elevated temperature. The idea is to bathe peritoneal surfaces in high concentrations of drug right after the surgeon has removed all visible tumor. A randomized trial comparing cytoreductive surgery alone versus surgery plus HIPEC in patients with stage III ovarian cancer who were not candidates for upfront surgery found that adding HIPEC improved median recurrence-free survival from about 10.7 months to 14.2 months and median overall survival from roughly 34 months to nearly 46 months.¹¹ International guidelines now include the option to add HIPEC to interval surgery for stage III ovarian cancer based on this evidence.¹²

Whether HIPEC specifically benefits patients whose peritoneal disease includes gastric metastases is less clear, because the trial populations were not broken down that way. Still, HIPEC is designed to treat peritoneal disease broadly, so if a gastric surface deposit is accessible to the heated chemotherapy solution during the procedure, it stands to receive the same exposure as disease elsewhere in the abdomen.

Targeted Therapies

For patients with certain molecular features, newer targeted drugs have expanded the treatment landscape. PARP inhibitors, a class of drugs that exploit weaknesses in the cancer cell’s DNA repair machinery, have shown strong results in patients whose tumors carry BRCA mutations or other signs of homologous recombination deficiency. In a large trial, the combination of olaparib (a PARP inhibitor) plus bevacizumab (an anti-angiogenesis drug) as first-line maintenance therapy extended median progression-free survival to 37.2 months in patients with BRCA-mutated, HRD-positive tumors, compared with 17.7 months for bevacizumab alone.¹³ Even in HRD-positive patients without a BRCA mutation, progression-free survival was substantially longer with the combination. These therapies work systemically, so a gastric metastasis carrying the same molecular signature as the primary tumor should respond as well.

In platinum-resistant recurrent disease, which is notoriously difficult to treat, a study of PARP inhibitor combined with bevacizumab showed an overall response rate of about 69% versus roughly 40% in the control group, with higher disease control rates and improved survival rates at one, two, and three years.¹⁴ This matters for patients with gastric metastases because disease that has spread widely enough to reach the stomach is more likely to recur and potentially develop platinum resistance, making access to these newer agents important.

Palliative Approaches for Stomach-Related Complications

When a gastric metastasis causes physical obstruction, bleeding, or severe symptoms that systemic therapy alone cannot quickly relieve, palliative interventions become critical. The goal shifts from eliminating the tumor to restoring the ability to eat, reducing pain, and preventing emergencies.

Self-expanding metal stents placed endoscopically through the narrowed segment of stomach or duodenum can reopen the passage enough for food and liquids to pass through. A study of patients with upper gastrointestinal obstruction from recurrent gynecologic cancer found that intraluminal stents provided useful palliation.¹⁵ In a broader series of patients with malignant gastric outlet obstruction who received stents, all were able to eat at least semisolid food afterward, with a median survival of about 6.4 months after the procedure.¹⁶ Stenting is not without risk — perforation can occur, though it is uncommon — but for a patient who is vomiting everything and cannot take in nutrition, it can be transformative.

When obstruction is lower in the bowel or when ascites (fluid buildup in the abdomen) complicates the picture, a venting gastrostomy tube may be placed. This tube allows stomach contents to drain out, relieving nausea and vomiting even when the underlying blockage cannot be fixed. A study of palliative venting gastrostomy in patients with malignant bowel obstruction and ascites found that inadequate gastric distension caused the initial placement attempt to fail in a notable fraction of cases, and that many patients needed additional procedures like paracentesis or an intraperitoneal catheter for fluid management.¹⁷ These are not curative procedures, but they address acute suffering and can help a patient stay out of the hospital and maintain some degree of normal life.

Nutritional Challenges and Why They Matter

When the stomach is directly affected by tumor, nutritional status deteriorates faster and more severely than in ovarian cancer without gastric involvement. The stomach’s role in food processing is compromised mechanically and sometimes hormonally, leading to malnutrition that weakens the patient, delays chemotherapy cycles, and worsens quality of life. Research on nutritional support in ovarian cancer emphasizes that malnutrition risk can accompany patients throughout the entire course of disease, and that regular screening, assessment, and timely nutritional treatment are key parts of comprehensive cancer care.¹⁴

Patients dealing with gastric metastases often benefit from small, frequent meals rather than three large ones, and from calorie-dense foods that deliver nutrition in small volumes. When eating by mouth is no longer feasible or sufficient, enteral feeding through a tube placed past the obstruction, or parenteral nutrition delivered intravenously, may be considered. The decision depends on life expectancy, treatment goals, and the patient’s wishes. Nutritional support does not fight the cancer directly, but it keeps patients strong enough to tolerate the treatments that do — and for patients receiving aggressive chemotherapy or targeted therapy, that distinction can be the difference between completing a treatment cycle and having to stop.

Prognosis and What Shapes It

Gastric metastasis from ovarian cancer generally signals advanced, widely disseminated disease, and the prognosis is poor.⁵ That said, outcomes vary considerably depending on a handful of factors. Platinum sensitivity is one of the strongest: a cancer that still responds to platinum-based chemotherapy opens the door to treatments with better track records. BRCA mutation status or broader HRD positivity further expands options, as these patients can access PARP inhibitors that have shown dramatic improvements in progression-free survival.¹³

The volume of residual disease after surgery also matters. If cytoreductive surgery achieves complete or near-complete removal of all visible disease, including any gastric component, survival tends to be longer. Performance status — basically, how well the patient is functioning day to day — affects both treatment eligibility and outcomes. A patient who is still relatively active and eating is a far better candidate for aggressive multimodal treatment than one who is bedbound and malnourished.

The rarity of this specific scenario means there are no large survival datasets dedicated to ovarian-to-stomach metastasis. Clinicians rely on broader ovarian cancer survival data, individual case reports, and their judgment about the patient’s overall disease trajectory. What the evidence does suggest is that identifying the gastric deposit early, confirming its origin accurately through tissue analysis, and treating it with the systemic regimen appropriate for ovarian cancer (rather than defaulting to gastric cancer protocols) gives the patient the best chance of benefit from the therapies that are available.

1
PubMed Central. Gastric metastases from gynaecologic tumors: case reports and review of the literature
2
PubMed Central. A Metastatic Gastric Tumor from Ovarian Cancer
3
PubMed. Clinicopathological features and treatment outcomes of metastatic tumors in the stomach
4
PubMed Central. Identifying symptoms of ovarian cancer: a qualitative and quantitative study
5
International Journal of Cancer Research & Therapy. Gastric Metastasis from Ovarian Carcinoma Revealed by Digestive Hemorrhage: Case Report
6
PubMed Central. Validation of FACT/GOG-AD subscale for ovarian cancer-related abdominal discomfort: a Gynecologic Oncology Group study
7
Gut and Liver. Gastric Metastasis from Ovarian Adenocarcinoma Presenting as a Submucosal Tumor without Ulceration
8
PubMed. Immunohistochemical biomarkers of value in distinguishing primary ovarian carcinoma from gastric carcinoma: a systematic review with statistical meta-analysis
9
PubMed Central. Isolated ovarian metastasis of gastric cancer: Krukenberg tumor
10
PubMed. Paclitaxel/carboplatin as first-line chemotherapy in advanced ovarian cancer: efficacy and adverse effects with special consideration of peripheral neurotoxicity
11
PubMed. Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer
12
JAMA Oncology. Hyperthermic Intraperitoneal Chemotherapy for Ovarian and Colorectal Cancer: A Review
13
PubMed. Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer
14
PubMed Central. Effect of PARP Inhibitor Combined with Bevacizumab on Platinum-Resistant Recurrent Ovarian Epithelial Carcinoma
15
PubMed. Management of upper gastrointestinal obstruction in advanced ovarian cancer with intraluminal stents
16
Surgical Laparoscopy, Endoscopy & Percutaneous Techniques. Endoscopic Stenting for Malignant Gastric Outlet Obstruction
17
PubMed Central. Palliative venting gastrostomy in patients with malignant bowel obstruction and ascites